+ T-cell count <200 cells/ml (AOR 3.4, 95% CI 1.06-11.007; P=0.03), time on ddI treatment (AOR 1.31, 95% CI 1.12-1.52; P=0.001) and previous abacavir exposure (AOR 3.01, 95% CI 1.18-7.67; P=0.02) were independently associated with abnormal LS. Conclusions: The prevalence of abnormal LS in HIVinfected patients without HBV or HCV coinfection is substantial. Long-term exposure to ddI is a major cause of liver damage in these patients.
Since the introduction of antiretroviral therapy (ART), the life expectancy of HIV-infected patients has substantially increased, as the risk of opportunistic infections or AIDS-related deaths have been notably reduced [1, 2] . In this context, liver disease has become a leading cause of morbidity and mortality in these patients [3] [4] [5] [6] . Chronic viral hepatitis caused by HBV or HCV infections is the main aetiology of liver disease in HIV-infected patients, although some other factors, such as alcohol consumption, non-alcoholic steatohepatitis or liver toxicity of some antiretroviral drugs, might contribute to this.
In the past few years, reports have brought attention to the emergence of unexpected cases of severe liver disease among HIV-infected patients without common risk factors for liver damage [7] [8] [9] [10] [11] . Maida et al. [8] have reported 32 cases of unexplained portal hypertension, some of them developing clinical decompensated liver disease. Authors have suggested that prolonged exposure to didanosine (ddI) is the main risk factor for this condition. Several reports [9] [10] [11] have raised the issue that non-cirrhotic portal hypertension might be a misdiagnosed cause of liver disease in HIV-infected patients and interestingly, in two of these reports, most of the patients had been previously exposed to ddI [10, 11] . As severe clinical events caused by portal hypertension, including the need for liver transplantation, might occur, it is important to recognize these 
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syndromes at an early stage. Moreover, the role of possible risk factors might be clarified. Indeed, although long-term exposure to ddI has been a common finding in previous reports, a cause-effect relationship has not yet been proven.
Transient elastography (TE) is a technique that assesses liver stiffness (LS). Several studies have shown that TE predicts accurately fibrosis and cirrhosis in several clinical contexts [12] [13] [14] [15] [16] [17] , including HIV infection [18] [19] [20] . In contrast to liver biopsy, TE is non-invasive, rapid and painless, and therefore well tolerated by the patient. In addition to its ability to predict fibrosis, LS correlates well with portal hypertension [21, 22] , the hallmark of the evolution of chronic liver disease. For these reasons, LS is an appropriate tool to explore a large population of asymptomatic patients at low risk of liver damage; thus, it also might be a useful parameter to identify early HIV-infected patients bearing unexplained severe liver disease.
The objective of our study was to search for the presence of abnormal LS in a cohort of HIV-infected patients without HBV or HCV coinfection and to assess the factors associated with abnormal LS in these patients.
Methods

Study design and patients
This was a cross-sectional prospective study. We included all consecutive HIV-infected patients without HBV or HCV coinfection who attended the Infectious Diseases Units of two tertiary care university hospitals in southern Spain (Hospital Universitario de Valme, Sevilla and Hospital Universitario Reina Sofía, Córdoba) from February 2006 to October 2008. During the study period, 748 HIV-infected patients were followed in the participating hospitals. Of them, 258 (35%) patients were negative for the presence of hepatitis B surface antigen and antibodies against HCV, and thus, were eligible for this study. At inclusion, patients completed a questionnaire, which included self-reported daily alcohol consumption, in addition to a clinical examination, and routine haematological, biochemical, immunological and virological assessments in order to rule out potential causes of liver disease.
Transient elastography evaluations
LS was determined using TE according to the standard technique [20] . We obtained at least 10 valid measures of LS in each patient before ending the examination. To guarantee the validity of TE results, we considered for analysis only the examinations with an interquartile range (IQR)<30% of the median value and a success rate of acquisitions >60%. These criteria have also been proposed by others [23] .
Laboratory determinations
Occult HBV and HCV infections were excluded in all patients who showed abnormal LS by testing plasma for the presence of HBV DNA and/or HCV RNA using PCR assays (AmpliPrep-Cobas ® TaqMan ® ; Roche Diagnostic Systems Inc., Meylan, France; detection limit 50 IU/ml). Acute hepatotoxicity and other conditions of liver disease were also excluded. Past drug or toxic exposure was investigated and determinations of ferritin, transferrin saturation, antiliver autoantibodies, antinuclear antibodies, α-1-antitrypsin and ceruloplasmin were performed in all patients showing abnormal LS to screen for haemochromatosis, autoimmune hepatitis, α-1-antitrypsin deficiency and Wilson's disease.
Histological assessment
Liver biopsy was proposed to those patients who showed abnormal LS. Samples were analysed by experienced pathologists in each centre who carefully searched for any recognizable aetiology of liver damage. Liver fibrosis was scored according to the Knodell histological activity index modified by Scheuer [24] . Nodular regenerative hyperplasia was defined as nodular architecture without extensive fibrosis or as the association of thickened and atrophic liver cell plates [25] .
Statistical analyses
The outcome variable of the study was the presence of abnormal LS, defined as an LS value ≥7.2 kPa. This value has shown a high accuracy in predicting significant fibrosis in HIV-HCV-coinfected patients [19] . The analysis included the associations between an abnormal LS and the following variables: age, gender, body mass index, self-reported alcohol consumption, previous intravenous drug use, estimated length of HIV infection, clinical AIDS, CD4 + T-cell count nadir and cell count at the time of TE, HIV viral load as well as previous and concomitant ART exposure (including antiretroviral drugs received before and at the time of TE evaluation).
Continuous variables are expressed as median (IQR) and categorical variables as numbers (percentages). The Student's t-test was used for comparisons between continuous variables if a normal distribution was followed and the Mann-Whitney U and the Kruskal-Wallis tests if not. Categorical variables were compared using the χ 2 test or Fisher's exact test when appropriate. The variables associated with an abnormal LS (with a P<0.1) in the univariate analysis were entered in the multivariate analysis. Logistic regression analyses with abnormal LS as the dependent variable were carried out. Associations with a P<0.05 were considered significant. The adjusted odds ratio (AOR) and the respective 95% confidence intervals (CIs) were also calculated. The statistical analysis was carried out using the SPSS version 14 statistical software package (SPSS Inc., Chicago, IL, USA).
Ethical aspects
The study was designed and conducted following the Declaration of Helsinki. The Ethics Committee of the Hospital Universitario de Valme approved the study. All the participants gave their written consent to participate in the study.
Results
Features of the study population
A total of 258 patients were included in the study. The main characteristics of the study population are summarized in Table 1 . TE evaluations provided valid measures of LS in all cases. The median (IQR) value of LS in the population was 4.9 kPa (4.1-6.1). In total, 222 (85%) patients were receiving ART at the time of the study. The median (IQR) length of ART exposure was 7.6 years (2.6-10.3).
Prevalence of abnormal liver stiffness
A total of 29 (11.2%) patients showed an LS value ≥7.2 kPa. Biochemical determinations to screen for common aetiologies of liver disease were negative in these patients. In addition, acute hepatotoxicity and occult HBV and HCV infections were ruled out in all of them; thus, the prevalence (95% CI) of abnormal LS in our population was 11.2% (7.36-15.04) and 20 (7.8%) patients showed LS values ≥9 kPa. The median (IQR) alanine aminotransferase, aspartate aminotransferase and γ-glutamyl transpeptidase levels in patients showing abnormal LS were 31 (22-53), 35 (23-41) and 92 (33-164), respectively. Only 11 (38%) out of the 29 patients with abnormal LS had an alanine aminotransferase level above the upper limit of normal.
Factors associated with abnormal liver stiffness
Univariate and multivariate analyses of the predictors of an LS value ≥7.2 kPa are summarized in Table 2 . A total of 18 (16.4%) patients who had previously received treatment with ddI had an LS value ≥7.2 kPa, whereas, this level was found in 11 (7.4%) of those who had never been treated with ddI (P=0.02). Among patients that had been exposed to ddI, time on ddI treatment was associated with LS. For example, 6 (10.3%) patients who received ddI for <4 years and 12 (25.5%) of those treated for >4 years showed abnormal LS (P=0.04). Figure 1 shows the proportion of patients that had LS values ≥7.2 kPa according to the length of ddI exposure.
The prevalence of abnormal LS was higher in patients that had been treated with abacavir than in those who had never received this drug (15 [ 
9).
In addition, recent or past exposure to the drug was not associated with the emergence of abnormal LS. Among patients that had been treated with abacavir, abnormal LS was seen in 10 (19.2%) patients who were treated with abacavir in the last 6 months, whereas it was seen in 5 (29.4%) of those who had been exposed to abacavir prior to the last 6 months (P=0.37).
In the logistic regression analyses, age, alcohol consumption, CD4 + T-cell counts, exposure to abacavir and time on treatment with ddI were independently associated with abnormal LS (Table 2) . Analyses using LS values ≥9 kPa as the outcome variable yielded similar results.
As alcohol consumption might exert some influence in the above mentioned results, we further analysed the risk factors for abnormal LS after excluding patients with moderate or severe alcohol consumption. who reported a daily alcohol intake <50 g/day. In total, nine (6.4%) patients who reported no alcohol consumption showed an abnormal LS, and it was also found in three (5.3%) of those who reported a daily alcohol consumption <50 g/day (P=0.7). An LS value ≥7.2 kPa was found in six (11.5%) patients previously exposed to abacavir and in six (4.1%) individuals who had been never treated with this drug (P=0.05). All six patients with abnormal LS previously exposed to abacavir had started this drug in the last 6 months. After multivariate analyses, age and time of treatment with ddI were the independent predictors of an LS value ≥7.2 kPa (Table 3) .
Histological findings
Liver biopsy was offered to all the 29 patients showing LS values ≥7.2 kPa. In total, 15 (52%) of them agreed to undergo this procedure. The main histological findings and the clinical, biochemical and epidemiological characteristics of these patients are shown in Table 4 . In four patients (cases 1, 2, 3 and 4), the clinical history and the histological findings suggested a diagnosis of alcoholic liver disease; two further patients (cases 5 and 6) with a previous history of alcohol consumption showed mild and moderate fibrosis, respectively. Notably, both patients had been exposed to ddI and abacavir. Cases 8 and 9 showed moderate fibrosis with histological findings suggesting non-alcoholic steatohepatitis and steatosis without inflammation or fibrosis, respectively, in the absence of features of the metabolic syndrome. Case 10 was a female patient who showed nodular regenerative hyperplasia. She reported mild alcohol consumption but liver biopsy did not show changes suggesting chronic alcoholic liver disease. Interestingly, this patient had received ddI for longer than 11 years. Case 11 was diagnosed with cryptogenic cirrhosis. Finally, four female patients (cases 12, 13, 14 and 15) showed moderate liver fibrosis without an identifiable aetiology and none of these patients reported alcohol consumption. Of note is the finding that three of them had a previous history of ddI treatment lasting longer than 4 years. 
Discussion
This study shows that the prevalence of abnormal LS in HIV-infected patients without HBV or HCV coinfection is substantial. Age, alcohol consumption, immunosuppression and previous exposure to ART are the main risk factors for this condition. Liver biopsy demonstrates the presence of liver fibrosis in almost all instances. These results also support the causal relationship between long-term exposure to ddI and liver fibrosis in this context. This is the first study, to our knowledge, that has evaluated the prevalence of abnormal LS in HIVinfected patients without chronic viral hepatitis. According to our results, the proportion of HIV-infected patients with abnormal LS is high, as 11% of the patients in our cohort showed LS values ≥7.2 kPa after excluding occult HBV and HCV infections and other aetiologies of liver disease. Of note is the finding that an abnormal LS was unexpected in the majority of these patients, as most of them had normal levels of liver enzymes. This fact reinforces the role of TE in the screening of HIV-infected patients for unexplained severe liver disease. Maida et al. [8] reported that the median value of LS at the moment of diagnosis was 13.8 kPa. It is reasonable to speculate that earlier evaluations of LS might have revealed abnormal values in these patients. In addition, the possibility that falsepositive results of TE might play a role in our results has been reasonably excluded in our study because liver biopsy, when available, confirmed the presence of some degree of liver damage in almost all instances. For these reasons, TE is probably a very appropriate tool to identify early HIV-infected patients bearing unexplained severe liver disease.
Some of the factors that were associated with the presence of abnormal LS in this study were not surprising. The role of alcohol in liver disease is well-established. In the same manner, immunosuppression has been uniformly associated with liver fibrosis in almost all of the studies conducted in HIV-infected patien ts with HCV coinfection [26] [27] [28] [29] [30] [31] [32] . In addition, some evidence suggests that HIV enhances transforming growth factor-β1 expression in hepatocytes and might itself contribute to the emergence of liver fibrosis [33] , which might in turn have been facilitated in patients with low CD4 + T-cell counts. Immunocompromised patients might have suffered from previous opportunistic infections in the liver, which might result in enhanced LS. Interestingly, we have found an association of previous exposure to ddI with the emergence of abnormal LS. This observation is in agreement with previous findings that have also linked ddI with the development of liver disease [7, 8, 34] . For example, a previous case control study describing 17 cases of cryptogenic liver disease [7] suggested that ddI might be involved in the development of unexplained portal hypertension. Cumulative exposure to ddI was the only independent predictor of cryptogenic liver disease in that study [7] . Moreover, these authors have recently reported the outcome of 32 cases of unexplained liver disease and removal of ddI improved clinical and biochemical parameters of liver function in these patients [8] . In addition, LS decreased from baseline after ddI discontinuation, which is in agreement with our findings of an association between abnormal LS and previous therapy with ddI. We have also observed a cumulative effect of ddI exposure; there was a trend to a linear association between the time of exposure to ddI and the frequency of abnormal LS. These findings strongly support the suggestion that ddI is the cause of liver damage in these patients. The mechanisms that have been postulated to explain the observations linking ddI to liver disease remain controversial and somewhat speculative. Endothelial damage in the portal tract caused by ddI, as previously described for other nucleoside analogues, such as azathioprine or 6-thioguanine [35] [36] [37] , is a potential explanation. Mitochondrial damage has also been suggested, as microvesicular steatosis was a common finding in the liver biopsy in one report [8] , although it was not in other studies [9, 11] . Nodular regenerative hyperplasia has been proposed as the final histological picture of the disease [8, 10, 11] , probably as a consequence of vascular injury in the portal system leading to portal hypertension and, frequently, portal thrombosis. In our study, we could obtain information of liver histology in half of the patients with abnormal LS. Liver biopsy identified one case of nodular regenerative hyperplasia in a patient with a past history of prolonged ddI exposure, which is in agreement with the above-mentioned studies. In addition, four patients showed moderate liver fibrosis without an identifiable cause. A total of two showed severe steatosis, although they did not report alcohol consumption and were not bearing features of the metabolic syndrome. Notably three of them had been exposed to ddI for several years, which suggests that ddI might play a role in this finding. A reasonable interpretation of these results is that ddI might induce liver damage by two mechanisms. Firstly, vascular injury caused by ddI might cause portal hypertension and nodular hyperplasia. Secondly, mitochondrial toxicity of ddI contributes to the development of steatosis and steatohepatitis, which eventually promote liver fibrosis. Nevertheless, further investigation is required, as current data are still scarce and conflicting; for example, nodular regenerative hyperplasia was not commonly found in our population and might not be the pivotal histological lesion associated with ddIrelated liver damage, as has been suggested [10] .
An unexpected finding was the association with abacavir. The role of abacavir in the emergence of cardiovascular disease is a controversial point of major concern, as it has been associated with an increased risk of cardiovascular events in some studies [38] [39] [40] . Conversely, other reports have not found such an association [41, 42] . The possible pathogenic mechanism for this observation is not known, although endothelial damage and the proinflammatory effect of abacavir in the vascular bed have been proposed [39] . To our knowledge, this is the first study suggesting a harmful effect of abacavir on the liver. Previous exposure to abacavir was an independent predictor of abnormal LS in our study, although we did not find an association with recent abacavir exposure or recent initiation of the drug, as has been suggested for cardiovascular events in the D:A:D study [38] and the ARNS cohort [40] , respectively. As has been hypothesized for cardiovascular disease, abacavir might also induce vascular injury in the portal system, in a similar manner as has been proposed for ddI-associated liver disease. Interestingly, exposure to ddI was also a predictor of myocardial infarction in the D:A:D study [38] , suggesting that these conditions might share common pathways. Nevertheless, we cannot draw definite conclusions because of the cross-sectional design and further research is necessary to confirm the association between abacavir and liver fibrosis found in this study.
Our study has a few limitations. Firstly, TE determinations were performed by more than one operator in the two participating hospitals; however, TE seems to be an observer-independent method as the reproducibility of TE is very high [43, 44] . For example, the intraclass correlation index between two observers was 0.978 in a recent study conducted in 246 HIV-HCV-coinfected patients carried out in the same hospitals as the current study [44] . Secondly, the threshold used to define LS as abnormal (a value of 7.2 kPa) was chosen using previous information of the diagnostic yield of TE to diagnose significant fibrosis in HIV-HCV-coinfected patients [19] ; however, there are no studies, so far, that have established and validated a specific cutoff for 'normal values' of LS. One study that examined the LS values of 429 healthy participants without apparent liver disease and with normal liver enzymes who underwent a medical check-up, reported that the mean value ±se of LS was 5.5 ±1.6 kPa [45] . Nevertheless, we explored the other cutoff point, 9 kPa, and obtained similar results, which reinforces the conclusions of this study. Liver histology was not available in all cases, as half of the patients refused to undergo a liver biopsy. This fact might not be surprising as liver biopsy is invasive and not always well tolerated by the patient. In addition, our population did not have viral hepatitis coinfection, and therefore, some patients were probably not aware of the importance of identifying potential liver damage; indeed, in the study by Maida et al. [8] liver biopsy was available in only one-third of the patients.
In summary, the present study demonstrates that the prevalence of abnormal LS in HIV-infected patients without HBV or HCV coinfection is high. In our opinion, screening of abnormal LS might be recommended if TE is accessible, as most of these patients might show normal liver enzymes. In addition to older age, alcohol consumption and immunosuppression, some antiretroviral drugs such as ddI and, perhaps, abacavir seem to be associated with this condition. Finally, our study provides additional evidence for a potential role for ddI in the development of liver fibrosis.
